Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia.

Blood cancer journal - 28 Oct 2022

Bidikian Aram, Kantarjian Hagop, Jabbour Elias, Short Nicholas J, Patel Keyur, Ravandi Farhad, Sasaki Koji, Issa Ghayas C

Abstract excerpt

While the clinical impact of mutations in the ABL1 gene on response to therapy in chronic phase chronic myeloid leukemia (CP-CML) is well established, less is known about how other mutations affect prognosis. In a retrospective analysis, we identified 115 patients with CML (71 chronic, 15 accelerated and 29 blast phase) where targeted next-generation sequencing of genes recurrently mutated in myeloid leukemias...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blast Crisis
Share to Chronic Myeloid Leukemia Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Leukemia, Myeloid

Share to Mutation

Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Share to Prognosis

Share to Repressor Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 36307398
DOI: 10.1038/s41408-022-00742-1
PMCID: PMC9616867

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia.PMID 36307398Read ↗

Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemiaSemantic proximity Read ↗

Genetic landscape of chronic myeloid leukemia.Semantic proximity Read ↗

ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia.Semantic proximity Read ↗

Prevalence and Prognostic Impact of ASXL1 Somatic Mutation in Patients with Chronic Myeloid Leukemia: A Systemic Review and Meta-AnalysisSemantic proximity Read ↗

The biology of chronic myeloid leukemia: an overview of the new insights and biomarkersSemantic proximity Read ↗

Poor Prognostic Implication of ASXL1 Mutations in Korean Patients With Chronic Myelomonocytic Leukemia.Semantic proximity Read ↗

ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study GroupSemantic proximity Read ↗

ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia.Semantic proximity Read ↗

Mutational landscape of chronic myelomonocytic leukemia and its potential clinical significance.Semantic proximity Read ↗

Frequent ASXL1 mutations in children and young adults with chronic myeloid leukemia.Semantic proximity Read ↗

Frequency and prognostic influence of ASXL1 mutations and its potential association with BCR-ABL1 transcript type and smoke in chronic myeloid leukemia patients.Semantic proximity Read ↗

Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.